Drug Discovery World

NOVEMBER 6, 2023

Cancer Research UK and the KWF Dutch Cancer Society (KWF) have announced a new multi-project strategic partnership to advance promising therapeutic agents for cancer. The CDD will sponsor and manage KWF-supported trials. Collaboration with like-minded organisations is essential to what we do.

Research 130

Research Clinical Trials Clinical Development International 130

Drug Discovery World

FEBRUARY 28, 2024

Lu Rahman selects some of the year’s interesting and noteworthy advances in cancer research drug discovery and development. In the UK, according to Cancer Research UK, around 167,000 people die from cancer in the UK each year. Research into new drugs and therapeutics is on-going and is helping drive mortality rates down.

Drug Development 162

Drug Development Research Clinical Trials Drugs 162

Drug Discovery World

AUGUST 9, 2023

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted Aleta Biotherapeutics a clinical trial authorisation (CTA) to evaluate biologic ALETA-001 in a Phase I/II clinical trial in patients with B-cell malignancies who are relapsed/refractory to CD19 CAR T cell therapy.

Clinical Trials 130

Clinical Trials Trials Therapies Licensing 130

Drug Discovery World

OCTOBER 11, 2023

Boehringer Ingelheim and CDR-Life entered a licensing agreement in May 2020 and announced the selection of an antibody fragment-based therapeutic candidate in September 2021.

Clinical Trials 130

Clinical Trials Treatment Trials FDA Approval 130

Drug Discovery World

AUGUST 16, 2024

CAR-T therapy for nasopharyngeal cancer enters Phase II trials The US Food and Drug Administration (FDA) has approved a Phase II clinical trial for Biosyngen’s BRG01, an EBV-specific CAR-T cell therapy. First claudin 18.2 monoclonal antibody.

Licensing 147

Licensing Licensing Drugs Clinical Trials 147

Drug Discovery World

FEBRUARY 1, 2023

Michael Sassano , CEO at SOMAÍ Pharmaceuticals looks at what’s needed throughout Europe to help increase access to medicinal cannabis and the current state of pharmaceutical research in this area. But for this market to become a reality, we need much more research into cannabis products and potential indications.

Clinical Trials 130

Clinical Trials Trials Pharmaceutical Companies Doctors 130

Drug Discovery World

JULY 2, 2024

In a Phase I trial, patients with metastatic kidney cancer who took a live biotherapeutic product alongside immunotherapy and enzymatic tyrosine kinase inhibitors experienced improved health outcomes. Participants’ gut microbiome were analysed via stool samples in the beginning for a baseline and then again 13 weeks into treatment.

Trials 147

Trials Treatment Clinical Trials Licensing 147

Drug Discovery World

JANUARY 2, 2024

Cancer Research Horizon’s Innovation Summit 2023 took place on 21 November 2023 at the Royal Society of Medicine, and included talks from researchers translating their research, as well as networking with members of the entrepreneurial ecosystem. As for Infinitopes, the company’s trials will begin in 2024.

Research 147

Research Vaccine Science Trials 147

Drug Discovery World

AUGUST 12, 2022

Pfizer has launched a Phase III clinical trial of a vaccine to protect people against Lyme disease, in collaboration with pharmaceutical company Valneva. . The trial will enrol up to 6,000 participants aged five years and older and will be conducted across 50 sites where Lyme disease is highly endemic. Juan Carlos Jaramillo M.D.,

Vaccine 130

Vaccine Disease Trials Pharmaceutical Companies 130

Conversations in Drug Development Trends

AUGUST 9, 2024

Authors: Matt Cooper, PhD, Executive Director, Therapeutic Strategy Lead, Oncology; Megan Morrison, Vice President, Asia Pacific Strategy Lead Adaptive trial designs have become essential in oncology, offering a flexible and efficient approach for conducting clinical trials.

Trials 80

Trials Clinical Trials Regulations FDA 80

Conversations in Drug Development Trends

OCTOBER 26, 2022

Bringing a psychedelic into a clinical trial setting is complex and requires a thorough operational approach to ensure the study’s success. Psychedelic trials need to be done with scientific rigor. Our team published recently in The Journal of Psychedelic Psychiatry exploring how we can bring more rigor to these trials.

Trials 97

Trials Clinical Trials Licensing Licensing 97

Perficient: Drug Development

OCTOBER 20, 2023

While it proved to be tricky to find an opening for an infant, we endeavored to compare in-home daycares and licensed facilities. In contrast, the licensed facilities we used maintained extended afternoon hours, providing a tad more flexibility for evening pickups. Luckily, Perficient is very family friendly.

Licensing 52

Licensing Licensing Doctors Regulations 52

Drug Discovery World

JUNE 1, 2023

A market research report published in late June 2018 by HTF market Intelligence Consulting suggested that the ADC market in China would grow exponentially by 2023 4. Under the terms of the licensing agreement, AstraZeneca will be granted an exclusive global license to research, develop, and commercialize LM-305.

Marketing 245

Marketing FDA Approval Licensing Licensing 245

Drug Discovery World

JULY 26, 2023

A Cancer Research UK-funded clinical trial has shown, for the first time, that a new class of antibody could benefit cancer patients whose existing treatments have stopped working. The drug, MOv18 IgE, was developed by researchers at King’s College London.

Clinical Trials 130

Clinical Trials Immune Response Drugs Trials 130

Drug Discovery World

MARCH 20, 2024

Cancer Research UK and the Norwegian Cancer Society (NCS) have announced a new multi-project strategic partnership to maximise the unique drug development capabilities of both countries. Suitable projects will then be brought into the CDD post-approval for its experienced team to plan, sponsor and run an early-phase clinical trial.

Drugs 130

Drugs Clinical Trials Licensing Licensing 130

Drug Discovery World

AUGUST 21, 2024

Adcendo and Multitude Therapeutics have signed a licensing agreement for the development of a novel, highly differentiated antibody-drug conjugate (ADC) targeting Tissue Factor (TF) with the development code ADCE-T02.

Licensing 130

Licensing Licensing Clinical Development Clinical Trials 130

Advarra

JUNE 14, 2024

A regulatory binder is essential for managing clinical trial documents, ensuring regulatory compliance, and facilitating audits. It organizes critical documents; provides easy access for trial monitors, auditors, and regulatory authorities; and serves as a reference for the research team.

Clinical Trials 40

Clinical Trials Trials Compliance FDA 40

Drug Discovery World

OCTOBER 3, 2023

Phase III trial data The WHO recommendation was based on pre-clinical and clinical trial data which showed good safety and high efficacy in four countries, making it the world’s second-ever WHO recommended vaccine for preventing malaria in children.

Vaccine 147

Vaccine Clinical Trials Licensing Licensing 147

LifeSciVC

JULY 17, 2024

Identifying the right targets, de-risking those targets, and then executing trials requires significant capital, strategic focus, and time. Fortunately, AbbVie felt the same way, which is why we initiated discussions to in-license AbbVie’s most promising CF pipeline programs.

Clinical Research 45

Clinical Research Disease Research Clinical Trials 45

Drug Discovery World

JULY 28, 2023

The top stories: Partnership could enhance antibody discovery for cancer research Cancer Research Horizons has signed a collaboration agreement to license the entire Twist Biopharma Solutions Library of Libraries. New eBook: Breakthroughs accelerating therapeutic antibodies The latest eBook by DDW is out now.

Clinical Trials 130

Clinical Trials Licensing Licensing Drugs 130

Predictive Oncology

MARCH 17, 2023

Cancer Research Horizons to incorporate PEDAL into future drug discovery processes to enable drug development on a global scale 11 marketed drugs 2nd largest oncology out-licensor globally 150+ active licenses 160+ new drugs into early-phase clinical trials $647 million revenue from royalties & IP $2.8

Research 52

Research Clinical Trials Licensing Licensing 52

The Pharma Data

OCTOBER 27, 2021

NYSE and TASE: TEVA) and MODAG GmbH today announced a strategic collaboration on the exclusive worldwide licensing and development of MODAG’s lead compound anle138b and a related compound, sery433. Small molecule candidate Anle138b targets disease modification for multiple system atrophy and other neurological disorders. About MODAG.

Licensing 52

Licensing Licensing Disease Small Molecule 52

The Pharma Data

MARCH 31, 2023

AstraZeneca has completed an exclusive global license agreement with KYM Biosciences Inc. CMG901 is currently being evaluated in a Phase I trial for the treatment of Claudin 18.2-positive CMG901 is currently being evaluated in a Phase I trial for the treatment of Claudin 18.2-positive

Licensing 40

Licensing Licensing Small Molecule Drugs 40

Drug Discovery World

MARCH 6, 2024

This second ODD allows research and development of a therapy for another form of the disease, Isolated Hypomyelination. Earlier last year the biotech successfully led a second round of investment, taking the total up to £13.2m ($16.7m), which will take it up to the start of in-human clinical trials later this year.

FDA 130

FDA Disease Therapies Drugs 130

Drug Discovery World

MARCH 27, 2024

These include the Gamaleya Federal Research Center of Epidemiology and Microbiology’s GamTBvac and the University of Zaragoza’s MTBVAC, both of which are currently in Phase III development and have demonstrated positive safety and efficacy results in clinical trials.

Vaccine 130

Vaccine Clinical Trials Licensing Licensing 130

Drug Discovery World

SEPTEMBER 16, 2022

A biologic therapy for very young children with moderate to severe eczema (or atopic dermatitis) has been shown to be safe and effective in an international trial. The therapy is already licensed in the UK for adults and children aged six to 18, and was approved by the FDA in June 2022 for use in younger children.

Therapies 130

Therapies Licensing Licensing Clinical Research 130

Drug Discovery World

JANUARY 15, 2024

Chiesi and Oak Hill Bio intend to continue a Phase IIb clinical trial in 2024 in the United States, Europe, and Japan. Evotec and the Crohn’s & Colitis Foundation Evotec has joined forces with the Crohn’s & Colitis Foundation, a non-profit organisation focused on research and patient support for inflammatory bowel disease (IBD).

Targeted Protein Degradation 147

Targeted Protein Degradation Drugs Small Molecule Licensing 147

Drug Discovery World

SEPTEMBER 27, 2023

“Approximately two-thirds of newly-diagnosed myeloma patients are not eligible for a transplant, and now, at long last, they’ll be able to benefit from a potentially life-extending treatment that could give them precious time with their loved ones,” said Shelagh McKinlay, Director of Research and Advocacy at blood cancer charity Myeloma UK.

Regulations 130

Regulations Licensing Licensing Therapies 130

Drug Discovery World

OCTOBER 21, 2022

Under an exclusive agreement, Jazz Pharmaceuticals will acquire development and commercialisation rights to Zymeworks’ zanidatamab across all indications and all territories except for those Asia/Pacific territories previously licensed by Zymeworks. billion, plus royalties on net sales. billion, plus royalties on net sales.

Licensing 130

Licensing Licensing Treatment Pharmaceuticals 130

Drug Discovery World

AUGUST 1, 2023

Partnerships Earlier this year cell-engineering company MaxCyte signed a strategic platform license (SPL) with biotechnology company Catamaran Bio. In return MaxCyte will receive platform licensing fees and program-related revenue.

Drugs 130

Drugs Licensing Licensing Engineering 130

The Pharma Data

DECEMBER 2, 2020

This License Agreement represents an important corporate milestone. The License provides EYAM with the exclusive right to develop several proprietary COVID-19 vaccine candidates in a self-amplifying mRNA vaccine platform. EYAM anticipates rapid commencement of animal trials for these COVID-19 vaccine candidates. ” Dr. .”

Licensing 52

Licensing Licensing Vaccine Virus 52

Drug Discovery World

APRIL 5, 2023

The drug, which is now called NXP800 and has already entered a Phase I clinical trial, was discovered by scientists at The Institute of Cancer Research, London. NXP800 has been licensed to oncology-focused biopharmaceutical company Nuvectis Pharma, which is leading the further development.

Clinical Trials 130

Clinical Trials Pharmacokinetics Drugs DNA 130

Drug Discovery World

AUGUST 21, 2023

Medications containing semaglutide such as Ozempic, licensed for diabetes, and Wegovy, for weight loss, are being studied to see if they can treat a range of different conditions, including addiction and dementia. It’s an exciting area,” he told The Guardian.

Clinical Trials 130

Clinical Trials Trials Treatment Licensing 130

FDA Law Blog: Drug Discovery

MARCH 13, 2023

Who better than people living with a condition to inform drug companies, physicians, academics, and the FDA on what it is like to live with their condition, what symptoms most impact their lives, what goes into their decision about whether to participate in a clinical trial, and what kind of treatment effects would be most meaningful to them?

Therapies 98

Therapies FDA Trials Clinical Trials 98

Drug Discovery World

APRIL 6, 2023

Olaparib is also licensed for use in patients with BRCA1 and BRCA2 mutations and advanced breast and pancreatic cancer, but it is not yet available on the NHS. A long scientific journey The decision has been welcomed by the Institute of Cancer Research (ICR).

Clinical Trials 130

Clinical Trials Licensing Licensing Treatment 130

Drug Discovery World

NOVEMBER 8, 2022

Merck has exercised its option to jointly develop and commercialise personalised cancer vaccine (PCV) mRNA-4157/V940 pursuant to the terms of its existing collaboration and license agreement with Moderna. . KEYNOTE-942 is an ongoing randomised, open-label Phase II trial that enrolled 157 patients with high-risk melanoma.

Vaccine 130

Vaccine Immune Response Research Laboratories Clinical Trials 130

Molecule Blog

JANUARY 9, 2023

The future of research is collaborative, digital, and highly autonomous. Research is built on data (and sometimes code) that routinely isn’t shared, affecting our ability to replicate science. Researchers make proposals to the system for projects that contribute to solving the disease. Patents today are not.

Research 52

Research Licensing Licensing Science 52